Revive Therapeutics (FRA:31R) EBITDA Margin %: 0.00% (As of Mar. 2026)


What is Revive Therapeutics EBITDA Margin %?

Revive Therapeutics FRA:31R +25.00% EBITDA Margin % is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Revive Therapeutics ranks worse than 104711.94% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Revive Therapeutics's EBITDA for the three months ended in Mar. 2026 was €-0.32 Mil. Revive Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Revive Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Revive Therapeutics  (FRA:31R) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Revive Therapeutics EBITDA Margin % Related Terms

Revive Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Revive Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revive Therapeutics EBITDA Margin % Chart

Revive Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Revive Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:31R vs ZTS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revive Therapeutics EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's EBITDA Margin % falls into.


Revive Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Revive Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-6.984/0
= %

Revive Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.319/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Revive Therapeutics (FRA:31R) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Revive Therapeutics and its competitors. According to the industry distribution chart, Revive Therapeutics ranks #999999 out of 955 companies in the Drug Manufacturers industry.
Is Revive Therapeutics' EBITDA Margin % too high?
Revive Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Revive Therapeutics ranks #999999 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Revive Therapeutics' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Revive Therapeutics ranks #999999 out of 955 companies for EBITDA Margin %. This places Revive Therapeutics in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Revive Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revive Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revive Therapeutics stock overvalued right now?
Revive Therapeutics (FRA:31R) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Revive Therapeutics (FRA:31R), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revive Therapeutics Business Description

Other Exchanges RVVTF:USARVV:Canada
Address 82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.